The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.

[1]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[2]  B. Scheithauer,et al.  The New WHO Classification of Brain Tumours , 1993, Brain pathology.

[3]  Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas , 1995 .

[4]  K. Zang,et al.  Correlation of histology, cytogenetics and proliferation fraction (Ki-67 and PCNA) quantitated by image analysis in meningiomas. , 1996, Pathology, research and practice.

[5]  A. Asai,et al.  Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas , 1996, Acta Neuropathologica.

[6]  L. Langford,et al.  Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. , 1996, Human pathology.

[7]  M. Samii,et al.  Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. , 1997, Journal of neurosurgery.

[8]  H. Takeuchi,et al.  Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. , 1997, Surgical neurology.

[9]  H. Budka,et al.  Proliferation and Dna fragmentation in meningioma subtypes , 1997, Neuropathology and applied neurobiology.

[10]  B. Scheithauer,et al.  Meningioma grading: an analysis of histologic parameters. , 1997, The American journal of surgical pathology.

[11]  E. Hedley‐Whyte,et al.  Progesterone and estrogen receptors in meningiomas: prognostic considerations. , 1997, Journal of neurosurgery.

[12]  C. Madsen,et al.  Ki-67 immunoreactivity in meningiomas--determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67. , 1997, Clinical neuropathology.

[13]  Hsu,et al.  MIB‐1(Ki‐67) index and transforming growth factor‐alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas , 1998, Neuropathology and applied neurobiology.

[14]  B. Scheithauer,et al.  The prognostic significance of MIB‐1, p53, and DNA flow cytometry in completely resected primary meningiomas , 1998, Cancer.

[15]  R. Prayson,et al.  MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. , 1998, Human pathology.

[16]  A. Probst,et al.  Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. , 1998, Human pathology.

[17]  R. Tanaka,et al.  Proliferative Potential of Recurrent Intracranial Meningiomas as Evaluated by Labelling Indices of BUdR and Ki-67, and Tumour Doubling Time , 1998, Acta Neurochirurgica.

[18]  R. Prayson,et al.  Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. , 1999, Archives of pathology & laboratory medicine.

[19]  K Arita,et al.  Recurrence of meningiomas , 2000, Cancer.

[20]  G. Barbagallo,et al.  Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. , 2000, Pathology, research and practice.

[21]  S. Torp,et al.  Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. , 2001, Clinical neuropathology.

[22]  Y. Takeshima,et al.  Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. , 2001, Human pathology.

[23]  Masayuki Nakajima,et al.  Significance of MIB-1 Staining Indices in Meningiomas: Comparison of Two Counting Methods , 2001, The American journal of surgical pathology.

[24]  S. Raab,et al.  Interobserver variability associated with the MIB‐1 labeling index , 2001, Cancer.

[25]  M. Souweidane,et al.  MIB-1 Staining Index of Pediatric Meningiomas , 2001, Neurosurgery.

[26]  K. Roessler,et al.  Topoisomerase II alpha as a reliable proliferation marker in meningiomas , 2002, Neurological research.

[27]  Chih‐Yi Hsu,et al.  Histopathology and MIB‐1 labeling index predicted recurrence of meningiomas , 2002, Cancer.

[28]  F. Giangaspero,et al.  Recurrent and atypical meningiomas--a multiparametric study using Ki67 labelling index, AgNOR and DNA Feulgen staining. , 2003, Clinical neuropathology.

[29]  J. Kuratsu,et al.  The expression of tissue factor correlates with proliferative ability in meningioma. , 2003, Oncology reports.

[30]  A. Korshunov,et al.  Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome , 2003, International journal of cancer.

[31]  K. Shimizu,et al.  Prognostic Significance of Cyclin A Expression in Meningiomas , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[32]  P. Korkolopoulou,et al.  Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. , 2003, Histology and histopathology.

[33]  J. Inazawa,et al.  A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. , 2003, Cancer genetics and cytogenetics.

[34]  H. Budka,et al.  In situ analysis of cell kinetics in human brain tumors , 1989, Acta Neuropathologica.

[35]  L. de Ridder,et al.  Primary resected meningiomas: relapses and proliferation markers. , 2004, In vivo.

[36]  M. Møller,et al.  No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry , 1997, Journal of Neuro-Oncology.

[37]  M. Samii,et al.  The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases , 2004, Acta Neurochirurgica.

[38]  K. Kunishio,et al.  Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expressions Correlate with the Recurrence of Intracranial Meningiomas , 2004, Journal of Neuro-Oncology.

[39]  J. Baumgartner,et al.  Meningioma in the pediatric population , 1996, Journal of Neuro-Oncology.

[40]  A. Chakrabarty,et al.  MIB1 proliferation index in meningiomas: does it predict recurrence? A clinicopathological study , 2004, British journal of neurosurgery.

[41]  N. Hashimoto,et al.  The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. , 2004, Surgical neurology.

[42]  J. Hainfellner,et al.  Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature , 2004, Neurosurgical Review.

[43]  L. de Ridder,et al.  The hTERT‐protein and Ki‐67 labelling index in recurrent and non‐recurrent meningiomas , 2005, Cell proliferation.

[44]  Paolo Cappabianca,et al.  Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors , 2007, Journal of Neuro-Oncology.

[45]  N. Altınörs,et al.  Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. , 2005, Clinical neuropathology.

[46]  S. Kropf,et al.  Different Activation of Mitogen-Activated Protein Kinase and Akt Signaling Is Associated with Aggressive Phenotype of Human Meningiomas , 2005, Clinical Cancer Research.

[47]  S. Lydersen,et al.  Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. , 2005, Clinical neuropathology.

[48]  T. Hirose,et al.  Expression of E‐cadherin and catenins in meningioma: Ubiquitous expression and its irrelevance to malignancy , 2005, Pathology international.

[49]  R. Prayson.  The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. , 2005, Advances in anatomic pathology.

[50]  W. Henn,et al.  Triple approach for diagnosis and grading of meningiomas: Histology, morphometry of Ki-67/feulgen stainings, and cytogenetics , 2005, Acta Neurochirurgica.

[51]  M. Tatagiba,et al.  Proliferation potential of spinal meningiomas , 2006, European Spine Journal.

[52]  Y. Sato,et al.  Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin. , 2005, Clinical neuropathology.

[53]  K. Kunishio,et al.  DNA topoisomerase IIα protein and mRNA expression in intracranial meningiomas , 2006, Brain Tumor Pathology.

[54]  A. Auvinen,et al.  Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression , 2006, Journal of Neuro-Oncology.

[55]  W Feiden,et al.  Automated nuclear segmentation in the determination of the Ki-67 labeling index in meningiomas. , 2006, Clinical neuropathology.

[56]  W. Papierz,et al.  Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. , 2006, Folia neuropathologica.

[57]  V. Barresi,et al.  Caveolin-1 in meningiomas: expression and clinico-pathological correlations , 2006, Acta Neuropathologica.

[58]  T. Hori,et al.  Clinical and radiological features related to the growth potential of meningioma , 2006, Neurosurgical Review.

[59]  F. Barbieri,et al.  Significance of cyclin D1 expression in meningiomas: A preliminary study , 2007, Journal of Clinical Neuroscience.

[60]  Yoo-Jin Kim,et al.  Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. , 2007, American journal of clinical pathology.

[61]  Y. Chung,et al.  Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[62]  S. Coons,et al.  Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue , 2008, Journal of Neuro-Oncology.

[63]  M. Vankalakunti,et al.  MIB‐1 immunolabeling: A valuable marker in prediction of benign recurring meningiomas , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[64]  Webster K. Cavenee,et al.  WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .

[65]  M. McDermott,et al.  Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. , 2007, Journal of neurosurgery.

[66]  M. Madani-civi,et al.  Pathodiagnostic parameters for meningioma grading , 2008, Journal of Clinical Neuroscience.

[67]  Nüket Üzüm,et al.  Histopathological Parameters with Ki-67 and bcl-2 in the Prognosis of Meningiomas According to WHO 2000 Classification , 2008, Tumori.

[68]  S. Powell,et al.  Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas , 2008, Neuropathology : official journal of the Japanese Society of Neuropathology.

[69]  F. Soylemezoğlu,et al.  The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. , 2008, Pathology, research and practice.

[70]  A. Sav,et al.  Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.